GILEAD SCIENCES, INC. - 8-K Filing
Gilead Sciences reported Q1 2026 revenue of $7.0 billion, up 4% YoY, driven by higher HIV product sales, Trodelvy, and Livdelzi. Non-GAAP diluted EPS was $2.03, up from $1.81 in Q1 2025. The company raised full-year product sales guidance to $30,000–$30,400 million, excluding Veklury, and announced the acquisition of Arcellx for $7.8 billion to expand its oncology pipeline. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GILD